EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)

Kenneth Ngure, Barbara A Friedland, Daniel W Szydlo, Sarah T Roberts iD, Morgan Garcia, Lisa Levy, Carolyne A Akello, Krishnaveni Reddy, Thesla Palanee-Phillips, Pippa Macdonald, Bekezela Siziba, Lydia Soto-Torres und 5 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0287525 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Kenneth Ngure und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Adolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by the HIV epidemic and face an array of challenges using proven behavioral and biomedical prevention methods. To address the urgent need for expanding prevention options, we evaluated the baseline preferences of HIV prevention methods among participants enrolled in the MTN-034/REACH crossover trial along with their stated product preference prior to product initiation.

Methods

AGYW aged 16–21 years were enrolled at 4 study sites: Cape Town and Johannesburg, South Africa; Kampala, Uganda; and Harare, Zimbabwe and randomly assigned to the sequence of using oral PrEP and the dapivirine ring for 6 months each, followed by a choice period in which they could choose either product (or neither) for an additional six months. Eligible AGYW were HIV-negative, not pregnant and using effective contraception for at least two months prior to enrollment. Descriptive statistics were used to summarize demographic and behavioral data while multinomial analysis was used to determine predictors of stated product preference (ring or oral PrEP).

Results

Of the 247 AGYW enrolled in REACH, 34% were aged 16–17 and 89% had a primary partner.The median age of sexual debut was 16 years and 40% had ever been pregnant. At screening, 35% of participants were diagnosed with a sexually transmitted infection (STI), 39% had an AUDIT-C score associated with harmful drinking and 11% reported intimate partner violence in the past 6 months. Overall, 28% of participants, had CESD-10 scores suggestive of depressive symptoms (≥12) in the past week. At baseline, similar proportions stated a preference for the ring and oral PrEP (38.1% and 40.5% respectively), with 19% of participants stating they preferred both products equally. Only study site was significantly associated with product preference (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdolescentFemaleHumansPregnancySouth AfricaUgandaZimbabweYoung AdultPyrimidines

Substanzen

Anti-HIV AgentsDapivirinePyrimidines

Autor:innen und Institutionen

  • School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
  • Department of Global Health, University of Washington, Seattle, WA, United States of America.
  • Population Council, Center for Biomedical Research, New York, NY, United States of America.
  • Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
  • Women's Global Health Imperative (WGHI), RTI International, Berkeley, California, United States of America.
  • FHI 360, Durham, North Carolina, United States of America.

ORCID-Profile: Sarah T Roberts

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Mental Health
  • National Institute of Health

Zitieren

APA

Ngure, K., Friedland, B. A., Szydlo, D. W., Roberts, S. T., Garcia, M., Levy, L., Akello, C. A., Reddy, K., Palanee-Phillips, T., Macdonald, P., Siziba, B., Soto-Torres, L., Hosek, S., Hillier, S. L., Nair, G., Celum, C., & van der Straten, A. (2023). Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). PLOS ONE. https://doi.org/10.1371/journal.pone.0287525

Vancouver

Ngure K, Friedland BA, Szydlo DW, Roberts ST, Garcia M, Levy L, et al. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). PLOS ONE. 2023. doi:10.1371/journal.pone.0287525

BibTeX
@article{Ngure2023,
  author = {Ngure, Kenneth and Friedland, Barbara A and Szydlo, Daniel W and Roberts, Sarah T and Garcia, Morgan and Levy, Lisa and Akello, Carolyne A and Reddy, Krishnaveni and Palanee-Phillips, Thesla and Macdonald, Pippa and Siziba, Bekezela and Soto-Torres, Lydia and Hosek, Sybil and Hillier, Sharon L and Nair, Gonasagrie and Celum, Connie and van der Straten, Ariane},
  title = {Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0287525}
}
Kostenlos starten →